SCRS Welcomes GlaxoSmithKline as a Global Impact Partner
Ellicott City, MD – The Society for Clinical Research Sites (SCRS) announces GSK as a Global Impact Partner (GIP). As a GIP, GSK will serve on the SCRS Global Impact Board and work closely with the organization’s Leadership Council on setting and working toward strategic initiatives.
GSK was a finalist for the 2016 SCRS Eagle Award honoring clinical research sponsors and CROs which are highly ranked by sites.
“GSK’s commitment to the sites through their collaboration with SCRS is a strong signal of the value they see in sites having a unified voice and wanting to be part of that dialogue and community,” said SCRS President, Christine Pierre. “We look forward to ongoing collaboration with GSK to ensure they benefit from the value of the SCRS community as well, which ultimately will strengthen the sponsor and site partnership.”
Anne Marie Inglis, Head of US Clinical Operations, GSK comments “We believe the support and continued development of investigational sites is a key component in clinical trial success. As the individuals actually working daily with clinical trial subjects, investigational sites offer keen insight into improving the clinical trial experience. The SCRS network offers GSK an opportunity to build stronger relationships with the site community and work together to enhance the conduct of clinical trials.”
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 4,000 research sites in 54 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About GlaxoSmithKline
GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
